Early 2026 has already seen two medtech acquisitions, both targeting cardiovascular technologies in markets with strong procedural growth.
While it is too early to predict overall deal activity for the year, the transactions offer insight into how strategics are approaching portfolio expansion and technology positioning.
One deal involves W. L. Gore and Associates, which said it will acquire Conformal Medical, a clinical-stage company developing the CLAAS AcuForm System for left atrial appendage occlusion, known as LAAO. Financial terms were not disclosed.
LAAO is a procedure used to reduce stroke risk in patients with atrial fibrillation, or AFib, a condition that causes an irregular heartbeat. The treatment seals a small pouch in the heart called the left atrial appendage where blood can pool and form clots.
Between 70 and 95 per cent of AFib patients are classified as non-valvular. These patients face a five times higher risk of stroke compared with the general population.
About 60 million people worldwide are estimated to live with AFib, leaving a large population potentially eligible for LAAO procedures.
The LAAO device market is valued at about US$2bn and is expected to grow at a high single-digit compound annual growth rate over the next five years.
Boston Scientific currently accounts for roughly 75 per cent of global device sales through its WATCHMAN devices, while Abbott is the second largest competitor with its Amulet products.
Conformal Medical’s CLAAS AcuForm system uses a foam-based design intended to adapt to complex and variable anatomies, offering what the company describes as a one-size-fits-most alternative to traditional nitinol frame devices.
The system is being evaluated in the CONFORM pivotal trial. According to Compass data, the company has raised about US$200m to date.
The acquisition is notable because Gore, a privately held company known for materials science innovation, has historically made relatively few outright acquisitions.
Separately, Haemonetics said it will acquire Irish medtech company Vivasure Medical for €100m in upfront cash, with up to €85m in milestone-based payments.
Haemonetics previously invested US$32.2m in Vivasure in 2023.
Vivasure develops polymer-based implants and delivery systems for minimally invasive vessel closure.
Its PerQseal platform is used to close large-bore vascular access sites created during procedures such as transcatheter aortic valve replacement, where a new heart valve is inserted through a catheter rather than open surgery.
Unlike mechanical closure methods that rely on sutures or plugs, PerQseal uses a patch-based approach that conforms to the vessel’s natural anatomy.
The patch is fully bioabsorbable, meaning it is gradually absorbed by the body within about six months.
The large-bore vascular closure market is growing at a high single-digit rate, supported by rising volumes of transcatheter valve procedures and endovascular aortic aneurysm repair.
The expected expansion of transcatheter mitral and tricuspid valve interventions could roughly double the addressable market for large-bore valve procedures over the next five years.
Together, the Gore and Haemonetics deals illustrate two different acquisition strategies. One targets long-term platform differentiation in a competitive market, while the other strengthens category leadership through a focused tuck-in acquisition.
The transactions also build on momentum seen late last year, when four medtech acquisitions were announced in December 2025.
Analysts say the early deals suggest acquisition activity in the sector could remain active as 2026 begins.
